Cemiplimab
Cemiplimab is a programmed death receptor-1 (PD-1)–blocking antibody or immune checkpoint inhibitor.
The drug has several indications, including the treatment of patients with:
- Metastatic basal cell carcinoma
- Locally advanced basal cell carcinoma
- Metastatic cutaneous squamous cell carcinoma
- Locally advanced cutaneous squamous cell carcinoma
- Non-small cell lung cancer
Provider Resources
